FINWIRES · TerminalLIVE
FINWIRES

Indian Equities Gain on Wednesday as US-Iran Talks Hopes Lift Sentiment

-- Indian equity benchmarks moved higher on Wednesday, each gaining over 1.5%, as expectations of renewed talks between the U.S. and Iran lifted sentiment.

The BSE Sensex rose 1,263.67 points, or 1.6%, to close at 78,111.24, while the NSE Nifty 50 gained 388.65 points, or also 1.6%, to settle at 24,231.30.

Markets reacted to reports indicating that Washington and Tehran could resume discussions shortly. U.S. President Donald Trump reportedly said talks may take place in Pakistan within the next two days. The development followed an inconclusive round of talks over the weekend and helped ease investor concerns.

Crude oil prices declined further, with Brent trading near $95 per barrel, supporting market sentiment.

Among stocks, Diamond Power Infrastructure rose over 2% after receiving a letter of intent worth 454.7 million rupees from Adani Electricity Mumbai, for cable supply from May 2026 to May 2027.

Wipro gained over 3% after saying it will acquire select customer contracts of U.S.-based Alpha Net Consulting and its subsidiaries for up to $70.8 million.

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062